<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020488</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068548</org_study_id>
    <secondary_id>NCI-01-C-0082</secondary_id>
    <secondary_id>MB-NAVY-00-02</secondary_id>
    <secondary_id>MB-NAVY-B00-038</secondary_id>
    <nct_id>NCT00020488</nct_id>
    <nct_alias>NCT00021515</nct_alias>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors</brief_title>
  <official_title>A Phase I &amp; Pharmacologic Trial Of Sequential Irinotecan As A 24-Hour IV Infusion, Leucovorin, &amp; Flurouracil As A 48-Hour IV Infusion In Adult Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating&#xD;
      patients who have advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the recommended phase II dose of irinotecan, leucovorin calcium, and&#xD;
           fluorouracil in patients with advanced solid tumors.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic and pharmacodynamic profiles of irinotecan and&#xD;
           fluorouracil in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the correlation of polymorphisms in the promoter region of the thymidylate&#xD;
           synthase gene with clinical toxicity and response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the correlation of polymorphisms in the uridine diphosphate&#xD;
           glucuronosyltransferase 1A1 gene promoter with the extent of SN-38 glucuronidation and&#xD;
           severity of diarrhea in patients treated with this regimen.&#xD;
&#xD;
        -  Assess any anti-tumor activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of irinotecan and fluorouracil.&#xD;
&#xD;
      Patients receive irinotecan IV continuously over 24 hours on days 1 and 15 and leucovorin&#xD;
      calcium IV over 30 minutes followed by fluorouracil IV continuously over 48 hours on days 2&#xD;
      and 16. Treatment repeats every 28 days for at least 2 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of irinotecan until the maximum tolerated&#xD;
      dose (MTD) is determined. Once the MTD of irinotecan has been determined, additional cohorts&#xD;
      receive escalating doses of fluorouracil until the MTD is determined. The MTD is defined as&#xD;
      the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study within 20 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced solid tumor that has failed standard therapy or for&#xD;
             which no standard therapy exists&#xD;
&#xD;
               -  Locally advanced, unresectable, primary or recurrent disease OR&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Previously untreated disease allowed provided this regimen represents reasonable&#xD;
             first-line therapy&#xD;
&#xD;
          -  No leukemia or lymphoma&#xD;
&#xD;
          -  No primary CNS malignancy or CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute granulocyte count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.6 mg/dL&#xD;
&#xD;
          -  AST/ALT no greater than 4 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.6 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other serious concurrent illness that would preclude study&#xD;
&#xD;
          -  No active infection requiring IV antibiotics&#xD;
&#xD;
          -  No known hypersensitivity to irinotecan&#xD;
&#xD;
          -  No marked intolerance to fluorouracil&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (at least 6 weeks for nitrosoureas or&#xD;
             mitomycin) and recovered&#xD;
&#xD;
          -  Prior short-infusion irinotecan allowed&#xD;
&#xD;
          -  Prior fluorouracil allowed&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  At least 8 weeks since prior strontium chloride Sr 89&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent cimetidine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Szabo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2003</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

